Silence Therapeutics (SLN) Liabilities and Shareholders Equity: 2019-2025
Historic Liabilities and Shareholders Equity for Silence Therapeutics (SLN) over the last 4 years, with Sep 2025 value amounting to $146.8 million.
- Silence Therapeutics' Liabilities and Shareholders Equity rose 19.53% to $146.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $700.0 million, marking a year-over-year increase of 29.28%. This contributed to the annual value of $202.6 million for FY2024, which is 69.64% up from last year.
- Latest data reveals that Silence Therapeutics reported Liabilities and Shareholders Equity of $146.8 million as of Q3 2025, which was down 11.16% from $165.2 million recorded in Q2 2025.
- In the past 5 years, Silence Therapeutics' Liabilities and Shareholders Equity ranged from a high of $202.6 million in Q4 2024 and a low of $5.4 million during Q1 2022.
- For the 3-year period, Silence Therapeutics' Liabilities and Shareholders Equity averaged around $118.4 million, with its median value being $142.0 million (2024).
- Per our database at Business Quant, Silence Therapeutics' Liabilities and Shareholders Equity decreased by 3.92% in 2021 and then skyrocketed by 825.94% in 2024.
- Quarterly analysis of 5 years shows Silence Therapeutics' Liabilities and Shareholders Equity stood at $11.5 million in 2021, then soared by 125.26% to $25.9 million in 2022, then skyrocketed by 361.39% to $119.4 million in 2023, then soared by 69.64% to $202.6 million in 2024, then grew by 19.53% to $146.8 million in 2025.
- Its Liabilities and Shareholders Equity stands at $146.8 million for Q3 2025, versus $165.2 million for Q2 2025 and $185.3 million for Q1 2025.